Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

Hatem Abou-OufMohammed AlshalalfaMandeep TakharNicholas ErhoBryan DonnellyElai DavicioniR Jeffrey KarnesTarek A Bismar

Published in: Journal of cancer research and clinical oncology (2018)

HDDA10 is of added value to GG and other clinical-pathological parameters in predicting BCR and Mets endpoint, especially in the low to intermediate patients' risk groups. HDDA10 prognostic value should be further validated prospectively in stratifying patients specifically in low to intermediate GS (GG1-2), such as active surveillance programs.

Keyphrases

prostate cancer
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
public health
gene expression
acute lymphoblastic leukemia
copy number
radical prostatectomy
single molecule